Clinical trials: Pharmacogenetics
Asthma
A 3-period Crossover Study With GSK573719 as Monotherapy in Adult Subjects With Asthma
This is a multi-national, randomized, double-blind, 3-period crossover, incomplete block design to evaluate 5 once-daily and 2 twice-daily doses of GSK573719 in combination with placebo.
- Trial name
- NCT01641692
- Testing
- GSK573719 (Sub-group cohort), Salbutamol/Albuterol
- Where
- 43 sites in United States, Bulgaria and 4 more
- Volunteers
- 350 people
- Sponsor
- GlaxoSmithKline
Thromboembolism
Applying Pharmacogenetic Algorithms to Individualize Dosing of Warfarin
The purpose of this study is to determine whether DNA analysis improves the efficiency of dosing and safety in patients who are being started on warfarin therapy.Warfarin, a blood thinner (anticoagulant) prescribed to 1-2 million…
- Trial name
- Coumagen-II (NCT00927862)
- Testing
- IWPC adapted genotype-guided dosing algorithm for warfarin, Modified IWPC genetic-guided warfarin dosing algorithm, Standard of care treatment
- Where
- United States
- Volunteers
- 2,415 people
- Sponsor
- Intermountain Health Care, Inc.
Efavirenz, Metabolism and Pharmacokinetics Changes
Determine the Effects of Gene Differences and Voriconazole on Enzyme CYP2B6 Activity in the Liver in Healthy Volunteers
The purpose of this study is to see if administration of medicines and genetic differences affects the activity of a liver enzyme called CYP2B6 in healthy volunteers.
- Trial name
- NCT01104376
- Testing
- Efavirenz, voriconazole
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Indiana University
Asthma
Pharmacogenetics of b2-Agonists in Asthma.
This study will help to find out if having a certain genetic makeup influences how a person with asthma responds to salmeterol, one of the two drugs in Advair(R).
- Trial name
- NCT00708227
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- Nemours Children's Clinic
HIV
Effects of CYP2B6 Genetic Polymorphisms on Efavirenz Pharmacokinetics
1. To see how the liver breaks down efavirenz by an enzyme called CYP2B6. It is suggested that when Efavirenz is taken repeatedly it may increase the amount of CYP2B6 in your liver and thus speed up your liver's ability to get…
- Trial name
- NCT00668395
- Testing
- Efavirenz
- Where
- 2 sites in United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Indiana University
Diabetes Mellitus, Gout
Pharmacogenetics of SGLT2 Inhibitors
Sodium-dependent glucose transporter-2 (SGLT2) inhibitors are a new class of anti-diabetic drugs, which increase urinary glucose excretion thereby promoting weight loss and decreasing plasma glucose levels.
- Conditions
- Diabetes Mellitus, Gout, Hyperuricemia
- Trial name
- SGLT2iPGx (NCT02462421)
- Testing
- Canagliflozin
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Pulmonary Disease, Chronic Obstructive
Long-term Safety Study for GSK573719/GW642444 in Japanese
The objective of this study is to evaluate the safety and tolerability of GSK573719/GW642444 Inhalation Powder 125/25 mcg once-daily.
- Trial name
- DB2115362 (NCT01376388)
- Testing
- GSK573719/GW642444 Inhalation Powder
- Where
- 23 sites in Japan
- Volunteers
- 131 people
- Sponsor
- GlaxoSmithKline
Cocaine Dependence, Opioid Dependence
Pharmacogenetics of Disulfiram for Cocaine
Previous research has shown that disulfiram, a medication sometimes used for treating alcoholism, discourages cocaine use among cocaine addicts who are undergoing methadone treatment.
- Trial name
- Disulfiram (NCT00149630)
- Testing
- Disulfiram, Methadone, CBT
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- Baylor College of Medicine
Congenital Bleeding Disorder, Haemophilia A With Inhibitors
Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept™2 Trial
This study is conducted globally. This study describes pharmacogenetic testing of saliva samples from patients who participated in the NN1731-3562 trial (adept™2) (NCT01392547).
- Conditions
- Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
- Trial name
- NCT02541942
- Testing
- No treatment given
- Where
- 15 sites in United States, Greece and 5 more
- Volunteers
- 19 people
- Sponsor
- Novo Nordisk A/S
Atrial Fibrillation, Pulmonary Embolism
Comparison of Warfarin Dosing Using Decision Model Versus Pharmacogenetic Algorithm
This is a prospective comparison of clinician dosing and a pharmacogenetic algorithm in diagnosed patients requiring warfarin therapy.
- Conditions
- Atrial Fibrillation, Pulmonary Embolism, Deep Vein Thrombosis
- Trial name
- NCT00511173
- Testing
- Warfarin Dose based on pharmacogenetics
- Volunteers
- 102 people
- Sponsor
- Creighton University
Type 2 Diabetes
Pharmacogenomics of Thiazolidinediones
The purpose of this study is to determine predictors of response to pioglitazone, an anti-diabetic medication. The investigators know from randomized clinical trials that some 30% of patients do not respond to this type of…
- Trial name
- PPAR (NCT01135394)
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Methamphetamine, Amphetamine Dependence
Study of Medical Treatment for Methamphetamine Addiction
Currently there are no medications approved for the treatment of methamphetamine addiction. Bupropion is an antidepressant that is approved by the Food and Drug Administration (FDA) for the treatment of depression and for…
- Conditions
- Methamphetamine, Amphetamine Dependence, Pharmacogenetics, Methamphetamine Dependence
- Trial name
- BUP PGx (NCT00833443)
- Testing
- Bupropion
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- University of California, Los Angeles
Pharmacogenetics
Delivery of Pharmacogenetic Testing in a Community Pharmacy Setting
This study aims to compare patient use of and satisfaction with community pharmacist-delivered pharmacogenetic (PGx) testing delivered along or as part of a medication therapy management (MTM) service.
- Trial name
- NCT02937545
- Testing
- Medication Therapy Management, Pharmacogenetic testing
- Where
- United States
- Volunteers
- 190 people, healthy volunteers welcome
- Sponsor
- Duke University
Acute Coronary Syndrome, Cardiovascular Diseases
Assessment of Prospective CYP2C19 Genotype Guided Dosing of Anti-Platelet Therapy in Percutaneous Coronary Intervention
This is a randomized, prospective, open label study to determine the cost-effectiveness of genotype-guided antiplatelet therapy.
- Trial name
- ADAPT (NCT02508116)
- Testing
- CYP2C19 genotyping
- Where
- 2 sites in United States
- Volunteers
- 509 people
- Sponsor
- University of Pennsylvania